- Market Realist•2 hours ago
After analysis of a Part A study of a combination of VX-661 and Ivacaftor, Vertex decided to stop the study, which included CF patients with two mutations.
- Market Realist•3 hours ago
The addressable population for Vertex Pharmaceuticals’ (VRTX) two commercialized products Kalydeco and Orkambi is currently 27,000.
- Market Realist•5 hours ago
Vertex is currently trying to expand Kalydeco’s label to include residual function CF (cystic fibrosis) patients.
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||88.20 x 100|
|Ask||88.25 x 100|
|Day's Range||87.26 - 88.66|
|52wk Range||75.90 - 134.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-78.07|
|Avg Vol (3m)||1,341,273|
|Dividend & Yield||N/A (N/A)|